JNJ•benzinga•
Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit
Summary
Johnson & Johnson raised its 2025 sales outlook and dividend, while Q1 results topped expectations driven by strong cancer drug performance.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 15, 2025 by benzinga